Refine Results
  1. "John Wiley & Sons"
Formats
  1. Journal Article (1322)
  2. Meeting Abstract (658)
  3. Conference Paper (127)
  4. Book Section (50)
  5. Review (26)
  6. Editorial (12)
  7. Research Letter (7)
  8. Correspondence (6)
  9. Book Whole (3)
  10. Guidelines (2)
  11. Miscellaneous (2)
Groups
  1. Department of Medicine (502)
  2. Population Sciences Research Program (486)
  3. Psychiatry and Behavioral Sciences, Department of (457)
  4. Psychiatry Service (335)
  5. Survivorship Research (291)
  6. Sloan Kettering Institute Faculty (259)

More Groups

People
  1. William Breitbart (85)
  2. Christian Nelson (76)
  3. Jimmie Holland (75)
  4. Klaus Busam (52)
  5. Lloyd Old (42)
  6. Andrew Roth (39)

More People

Years
  1. 2022 (58)
  2. 2021 (106)
  3. 2020 (111)
  4. 2019 (68)
  5. 2018 (95)
  6. 2017 (96)

More Years

Publications
  1. Psycho-Oncology (561)
  2. International Journal of Cancer (249)
  3. British Journal of Haematology (220)
  4. Journal of Cellular Biochemistry (178)
  5. Annals of the New York Academy of Sciences (112)
  6. Seminars in Surgical Oncology (76)

More Publications

Publishers
  1. John Wiley & Sons (2215)

Results (2215)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M.; Shah, N.; Alencar, A.; Gerson, J.; Patel, M.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial
    Meeting Abstract

    Musiek, A.; Whittaker, S.; Horwitz, S.; Bagot, M.; Huen, A.; Fisher, D.; Haun, P.; Vermeer, M.; Ito, T.; Dwyer, K.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Exploratory analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
    Meeting Abstract

    Harrison, C.; Verstovsek, S.; Salama, M. E.; Mascarenhas, J.; Talpaz, M.; Mesa, R.; Vannucchi, A. M.; Rampal, R. K.; Oh, S.; Olteanu, H.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis - Update of clinical and translational data from the ongoing MANIFEST trial
    Meeting Abstract

    Curto-Garcia, N.; Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Vannucchi, A. M.; Verstovsek, S.; Harrison, C.; Bose, P.; Schiller, G. J.; Rampal, R.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab in combination with rituximab and lenalidomide in relapsed or refractory follicular lymphoma: Preliminary phase 1/2 results
    Meeting Abstract

    Linton, K. M.; Wahlin, B.; Leppä, S.; Morschhauser, F.; Elliott, B.; Liu, T.; Stirner, M. C.; Abbas, A.; Falchi, L.
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A.; Pagel, J.; Coombs, C.; Shah, N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T.; Woyach, J.; Wierda, W.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory follicular lymphoma who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Chaganti, S.; Cwynarski, K.; Cunningham, D.; Locke, F. L.; Miklos, D. B.; Jacobson, C. A.; Perales, M. A.; Kersten, M. J.; Oluwole, O. O.; Ghobadi, A.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukaemia: Final 5-year results from the BFORE trial
    Meeting Abstract

    Milojkovic, D.; Brümmendorf, T. H.; Cortes, J. E.; Gambacorti-Passerini, C.; Clark, R. E.; Le Coutre, P.; García-Gutierrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma: Results from the phase III POLARIX study
    Meeting Abstract

    Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save